U.S. Wealth WatcherCelebrating Political Fortunes
‹ Lobbying

Inozyme Pharma

MA · 2 filings, 2025

Lobbying spend · 2025
$20K
to shape legislation
About the organization

INZ-701 is a recombinant ENPP1 enzyme developed to treat some genetic disorders that prevent normal production of ENPP1. It is developed by Inozyme Pharma. via Wikipedia ↗

1Lobbies on

Its filings list: Pharmacy

2Through these firms · 1

THE KPM GROUP DC LLC

3Bills moving in its lanes

No bill names this company outright; these are recent bills in the sectors it lobbies.